Abstract
Carbonic anhydrase IX (CA IX) is a tumor associated protein, since it is highly expressed in a multitude of carcinomas, while it is present in a limited number of normal tissues. It is a multi-domain protein consisting of an N-terminal proteoglycan-like (PG) domain, a catalytic domain, a trans-membrane portion (TM) and an intracytoplasmatic (IC) segment. These domains have peculiar biochemical and physiological features. Among these, only the PG domain is unique among the CA family. This review focuses on the most recent molecular and catalytic features uncovered of this enzyme, the role of its different domains in tumor physiology, and its three dimensional structure which has recently been solved. In addition, we present recent advances in the development of antibodies and small inhibiting molecules able to target CA IX for diagnostic and therapeutic applications.
Keywords: Anti-tumor drugs, carbonic anhydrase IX, inhibitors, monoclonal antibody, structure based drug design, Carbonic anhydrase, tumor, intracytoplasmatic, enzyme, carcinomas
Current Medicinal Chemistry
Title: Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs
Volume: 19 Issue: 6
Author(s): S. M. Monti, C. T. Supuran and G. De Simone
Affiliation:
Keywords: Anti-tumor drugs, carbonic anhydrase IX, inhibitors, monoclonal antibody, structure based drug design, Carbonic anhydrase, tumor, intracytoplasmatic, enzyme, carcinomas
Abstract: Carbonic anhydrase IX (CA IX) is a tumor associated protein, since it is highly expressed in a multitude of carcinomas, while it is present in a limited number of normal tissues. It is a multi-domain protein consisting of an N-terminal proteoglycan-like (PG) domain, a catalytic domain, a trans-membrane portion (TM) and an intracytoplasmatic (IC) segment. These domains have peculiar biochemical and physiological features. Among these, only the PG domain is unique among the CA family. This review focuses on the most recent molecular and catalytic features uncovered of this enzyme, the role of its different domains in tumor physiology, and its three dimensional structure which has recently been solved. In addition, we present recent advances in the development of antibodies and small inhibiting molecules able to target CA IX for diagnostic and therapeutic applications.
Export Options
About this article
Cite this article as:
M. Monti S., T. Supuran C. and De Simone G., Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs, Current Medicinal Chemistry 2012; 19 (6) . https://dx.doi.org/10.2174/092986712799034851
DOI https://dx.doi.org/10.2174/092986712799034851 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery Mechanisms of Action of DNA-Damaging Anticancer Drugs in Treatment of Carcinomas: Is Acute Apoptosis an “Off-Target” Effect?
Mini-Reviews in Medicinal Chemistry Heat Shock Protein 70s as Potential Molecular Targets for Colon Cancer Therapeutics
Current Medicinal Chemistry Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets Macromolecular Drug Targets in Cancer Treatment and Thiosemicarbazides as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry The Novel Synthesized Pyridazinone Derivates had the Antiproliferative and Apoptotic Effects in SHSY5Y and HEP3B Cancer Cell Line
Letters in Organic Chemistry Prodrugs in Photodynamic Anticancer Therapy
Current Pharmaceutical Design Recent Advances in Delivery of Cytokines, Growth Factors, and Molecules of Therapeutic Interest from Hyaluronan-based Hydrogels
Current Tissue Engineering (Discontinued) Integrin Function and Signaling as Pharmacological Targets in Cardiovascular Diseases and in Cancer
Current Pharmaceutical Design DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy
Current Cancer Drug Targets Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets Vitamin D and Vitamin D Analogs in Cancer Treatment
Current Drug Targets Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics The Application of Optical Technology in Microfluidic Systems
Current Proteomics Non-invasive Biodiversified Sensors: A Modernized Screening Technology for Cancer
Current Pharmaceutical Design Identification of a Novel Peptide Ligand of Human Transfrrin Receptor 1 for Targeted Tumor Delivery Drug
Protein & Peptide Letters A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry Secreted Heat Shock Protein-90α: A More Effective and Safer Target for Anti-Cancer Drugs?
Current Signal Transduction Therapy Perspectives on Medicinal Properties of Mangiferin
Mini-Reviews in Medicinal Chemistry Targeting SKCa Channels in Cancer: Potential New Therapeutic Approaches
Current Medicinal Chemistry